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SCIENTIFIC EDITORIAL
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Besides  evidence-based  guidelines  issued  by  professional  medical  societies  and  the  devel-
opment  of  new  drugs,  stroke  prevention  is  fundamentally  affected  by  the  way  in  which
scientiﬁc  knowledge  is  applied  and  novel  therapies  are  implemented  in  routine  clinical
practice.  Sabouret  et  al.,  in  this  issue  of  the  journal,  present  important  data  about  the
‘‘real-life’’  medical  practice  of  stroke  prevention  in  a  large  sample  of  patients  with  atrial
ﬁbrillation  (AF).  The  aims  of  their  observational  study  were  to  reﬂect  the  prescription
behaviors  of  general  practitioners  (GP),  who  are  signiﬁcantly  involved  in  the  primary  and
secondary  prevention  of  stroke  in  patients  with  AF,  and  to  compare  their  results  with  the
European  Society  of  Cardiology  (ESC)  guideline  recommendations  for  stroke  prevention
issued  in  2010  and  updated  in  2012  [1,2].  Data  were  collected  from  a  representative  net-
work  of  1200  GP  ofﬁces  in  France.  The  population  consisted  of  15,623  adults  with  AF  who
attended  at  least  one  GP  consultation  between  July  2010  and  June  2011.  The  patients’
mean  CHADS2  score  was  1.5  ±  1.1  and  their  mean  CHA2DS2-VASc  score  was  2.9  ±  1.5.  In
terms  of  adherence  to  the  2010  ESC  guidelines  on  stroke  prevention  in  AF,  the  study  showed
that  only  56.3%  of  the  patients  received  the  guideline-recommended  antithrombotic  ther-
apy,  while  it  was  overused  in  11.2%  of  patients  and  underused  in  13.0%.  According  to  the
CHA2DS2-VASc  score,  as  recommended  in  the  2012  ESC  guidelines,  adherence  to  guideline-
recommended  therapy  was  even  lower.  However,  as  noted  by  the  authors,  this  ﬁnding  has
to  be  interpreted  with  caution  because  the  survey  was  completed  before  publication  of
the  updated  guidelines.
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aimed  at  increasing  the  implementation  of  guidelines  in42  
These  results  highlight  the  difﬁculty  of  widespread
mplementation  of  guidelines  in  clinical  practice  from  the
erspective  of  the  professionals  actually  involved  in  stroke
revention  in  AF.  The  gap  between  science  and  clinical
ractice  has  been  emphasized  previously.  The  reasons  for
his  gap  can  be  categorized  into  two  main  themes,  the  ﬁrst
eing  practical  limitations  to  the  use  of  oral  anticoagu-
ants,  and  the  second  to  lack  of  knowledge  or  usual  use  of
uidelines  in  clinical  practice.  Although  the  evidence  sup-
orting  the  efﬁcacy  of  warfarin  in  stroke  prevention  leaves
ittle  room  for  interpretation,  the  practical  limitations  asso-
iated  with  this  oral  anticoagulant  are  clear.  The  array
f  warfarin  limitations  includes  its  unpredictable  pharma-
okinetics  and  pharmacodynamics  and  narrow  therapeutic
ndex.  These  inherent  limitations  explain  why  patients  and
hysicians  may  have  problems  initiating  and  adhering  to
arfarin  therapy.  Warfarin  is  underutilized  in  most  clini-
al  practice  settings  outside  of  clinical  studies.  And  even
hen  the  drug  is  initiated,  the  intensity  of  anticoagulation
s  often  inadequate.  The  study  by  Sabouret  et  al.  focuses  on
nticoagulant  treatment  with  vitamin  K  antagonists  (VKAs).
ther  ‘‘novel’’  drugs  have  entered  the  market,  leading  to
 decline  in  the  use  of  VKAs,  as  documented  recently  [3],
nd  which  reported  a  signiﬁcant  decline  in  the  propor-
ion  of  patients  with  AF  starting  warfarin  concurrent  with
he  availability  of  non-vitamin  K  oral  anticoagulant  agents
NOACs).  NOACs  present  a  promising  alternative  to  over-
ome  the  limitations  of  warfarin.  Their  convenient  route
f  administration,  with  a  ﬁxed  dose  and  lack  of  require-
ent  for  coagulation  monitoring,  may  translate  into  better
dherence  to  guideline-recommended  therapy.  But  there
s  still  some  way  to  go,  as  the  use  of  NOACs  for  stroke
revention  in  AF  is  still  suboptimal  [4].  The  EURObser-
ational  Research  Programme  Atrial  Fibrillation  (EORP-AF)
ilot  General  Registry  provides  contemporary  data  on  oral
nticoagulation  prescribed  by  European  cardiologists  for
F.  Although  the  uptake  of  VKA  oral  anticoagulation  has
mproved  since  the  Euro  Heart  Survey  was  conducted  a
ecade  ago,  antiplatelet  therapy  is  still  commonly  pre-
cribed,  with  or  without  oral  anticoagulation,  and  elderly
atients  are  commonly  undertreated.  Overall,  95.6%  of
atients  with  a  score  ≥  1  received  antithrombotic  therapy,
0.5%  with  oral  anticoagulation.  However,  83.7%  of  those
ith  a  score  ≥  2  received  antithrombotic  therapy,  70.9%  with
ral  anticoagulation.  VKAs  were  used  in  64.1%  and  NOACs  in
.9%  [5].
In  the  present  study  by  Sabouret  et  al.,  the  decision-
aking  for  thromboprophylaxis  was  largely  the  responsibil-
ty  of  the  GP.  Many  reports  have  shown  major  discrepancies
etween  provider  specialty  regarding  treatment  strategies
n  AF.  Detailed  educational  programmes  on  the  efﬁcacy,
afety  and  limitations  of  these  treatments  are  urgently
eeded  to  improve  rates  of  use  of  appropriate  antithrom-
otic  therapy.  As  illustrated  by  the  ﬁndings  reported  by
abouret  et  al.,  alongside  other  sources  that  show  strongly
onsistent  data,  these  programmes  should  be  especially  ded-
cated  to  GPs  and  internal  medicine  physicians.  Sabouret
t  al.’s  study  also  raises  the  issue  of  the  difﬁculty  of
mplementing  guideline  recommendations  because  of  their
ultiplication:  the  simultaneous  use  of  old  and  new  guide-
ines,  or  of  guidelines  issued  by  different  organizations,
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an  lead  to  a  degree  of  confusion  or  contradictory  guid-
nce.
Observational  studies  and  phase  4  clinical  trials  are
ssential  in  providing  data  on  elderly  patients,  who  are  pri-
arily  affected  by  AF  [6,7].  In  this  ‘‘real  world’’  cohort  from
he  AFIGP  survey,  the  mean  age  of  the  patients  (74.6  years)
as  greater  than  that  of  patients  included  in  recent  phase
 clinical  trials  on  antithrombotic  therapy  in  non-valvular  AF
71.5  years).  It  was  also  very  close  to  the  cut-off  of  75  years,
hich  adds  an  additional  point  on  the  CHA2DS2-VASc  score,
ut  is  also  an  additional  risk  factor  for  bleeding  in  the  HAS-
LED  score  [8]. Advanced  age  is  frequently  an  exclusion
riterion  in  clinical  trials.  The  comparative  safety  of  oral
nticoagulant  therapy  in  elderly  patients  with  non-valvular
F  was  reported  recently,  using  data  from  the  Medicare
atabase  [7]. The  study  involved  134,414  patients  with  AF
lder  than  65  years  who  were  followed  over  2 years  (between
010  and  2012);  the  patients’  risk  factors  were  assessed
sing  the  CHADS2  and  HAS-BLED  scores.  Anticoagulant  treat-
ent  with  warfarin  was  noted  in  41—43%  of  the  patients
ged  65—84  years  and  in  only  16%  of  those  older  than
5  years.
Interestingly,  the  report  by  Sabouret  et  al.  provides
nformation  on  anticoagulant  prophylaxis  for  stroke  pre-
ention  in  a single  western  European  country.  Guidelines
ublished  by  the  ESC  and  other  societies  have  tried  to
ecommend  a  uniform  evidence-based  approach  to  manage-
ent.  Despite  the  availability  of  such  guidelines  and  efforts
o  improve  their  implementation,  differences  in  adherence
o  recommended  treatments  are  still  evident.  Therefore,
he  results  should  be  analyzed  in  view  of  country  differ-
nces  in  patient  characteristics  and  management  practices.
ndeed,  the  ﬁndings  from  the  EORP-AF  registry  have  shown
ifferences  between  countries  and  regions  within  Europe:
 CHA2DS2-VASc  score  ≥  2  was  highest  in  East  and  South
ountries  (93.0  and  95.3%,  respectively)  versus  80.8%  in  West
ountries  (P  <  0.0001);  a  HAS-BLED  score  ≥  3  was  also  highest
n  East  and  South  countries  (18.0%  and  29.2%,  respectively)
ompared  with  4.8%  in  West  countries  (P  <  0.0001).  Use
f  oral  anticoagulation  in  West,  East,  and  South  countries
as  72.0%,  74.7%,  and  76.2%,  respectively,  and  antiplatelet
herapy  was  used  alone  in  13.6%,  15.4%,  and  12.4%  [9].
orldwide,  adequate  antithrombotic  therapy  is  inconsistent
t  global,  country  and  regional  levels,  and  may  be  inﬂuenced
y  factors  including  the  degree  of  awareness  of  updated
uidelines.  While  in  Europe  oral  anticoagulants  are  used  in
early  60%  of  patients  with  AF,  outside  of  Europe,  in  the
nited  States,  registry  data  indicate  a  lower  use  of  oral
nticoagulants  (i.e.  50%).  The  same  is  observed  in  Asia  ver-
us  Japan  and  non-Asian  regions  (i.e.  36%  vs  54%  and  55%,
espectively)  [10].
In  conclusion,  the  present  study  provides  systematic
ollection  of  contemporary  data  on  the  current  manage-
ent  and  treatment  of  AF  by  GPs  in  France.  Compliance
ith  evidence-based  treatment  guidelines  for  patients  at
ow  or  high  risk  of  stroke  remains  suboptimal.  Observa-
ional  data  such  as  these  are  key  for  generating  measureslinical  practice,  encompassing  practical  and  organizational
spects,  educational  efforts,  and  improvements  in  access  to
herapy.
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